AUDA-NEPAD hands over key Health Security Programmes to African Medicines Agency in landmark continental transition

0

“This milestone underscores our responsibility as the African Union’s premier continental development agency to ensure that AMA is fully capacitated to discharge its regulatory responsibilities,” – AUDA-NEPAD Chief Executive Officer H.E. Nardos Bekele-Thomas

IMG-20260123-WA0003

Participants from across Africa at the AUDA-NEPAD handover.

January 23, 2026 – Lusaka

Africa’s journey toward stronger health security and regulatory self-reliance reached a historic milestone this week as the African Union Development Agency (AUDA-NEPAD) formally handed over two flagship continental health programmes to the African Medicines Agency (AMA), FRANCIS LUNGU reports.

The transition was sealed during a high-level Joint Formal Handover Session held in Lusaka from January 22 to 23, marking the transfer of the African Medicines Regulatory Harmonization (AMRH) programme and the African Union Smart Safety Surveillance (AU-3S) initiative to the newly operational AMA.

The handover concludes more than 17 years of institution-building by AUDA-NEPAD and represents a decisive step in strengthening Africa’s capacity to regulate medicines and medical products.

Participants from across Africa at the AUDA-NEPAD handover.

It involved the transfer of regulatory assets, systems, processes, and technical resources developed over nearly two decades to ensure a smooth, seamless, and non-disruptive assumption of responsibilities by the AMA.

Speaking at the event, AUDA-NEPAD Chief Executive Officer H.E. Nardos Bekele-Thomas described the milestone as a reflection of the agency’s core mandate to build sustainable continental institutions.

“This milestone underscores our responsibility as the African Union’s premier continental development agency to ensure that AMA is fully capacitated to discharge its regulatory responsibilities,” she said.

“AMA is anchored in the strong legacy of our flagship health programmes—AMRH, launched in 2009, and AU-3S, launched in 2020—which have served as the bedrock for safeguarding public health and ensuring access to quality medical products across Africa.”

The AMRH programme has played a central role in harmonising medicines regulation across regional economic communities, while AU-3S strengthened pharmacovigilance and safety surveillance systems.

Their integration into AMA is expected to significantly enhance Africa’s ability to guarantee access to safe, effective, and high-quality medicines.

The Lusaka session brought together senior leadership from across the African Union system, including representatives of the African Union Commission, the Commissioner for Health, Humanitarian Affairs and Social Development, the Director Generals of Africa CDC and AMA, and the Government of Rwanda, the host country of the AMA.

The transition also highlights AUDA-NEPAD’s broader institutional legacy, having previously supported the establishment of key continental bodies such as the African Peer Review Mechanism (APRM), Smart Africa, SANBio, and the African Committee of Experts on the Rights and Welfare of the Child (ACERWC).

As the African Union’s development delivery arm for Agenda 2063 and the Short-Term Strategy and Implementation Plan (STYIP), AUDA-NEPAD reaffirmed its commitment to building specialised institutions that advance Africa’s long-term development goals in partnership with member states and strategic partners.

The successful handover of AMRH and AU-3S to AMA signals a new chapter for African health governance, reinforcing the continent’s resolve to act collectively “as one family under the African Union” and accelerate progress toward the aspirations of Agenda 2063.

The African Medicines Agency is the African Union’s continental body mandated to regulate medicines and medical products, ensuring that all products used across Africa meet agreed standards of safety, quality, and effectiveness.

AMA, therefore is an important body for Africa which faces a high level of imported counterfeited medicine, putting at risk the health of 1.4billion citizens of the continent.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may have missed

绝妙集团公布50亿美元投资计划​作者:海伦·博瓦利亚(Hellen Bwalya)​绝妙集团有限公司(Wonderful Group of Companies Limited)通过其子公司赞比亚联合资本化肥有限公司(United Capital Fertilizer Zambia Company Limited),在其工业园区举行的奠基仪式上,正式启动了一项跨越2025年至2030年的50亿美元中长期工业投资宏伟计划。集团首席执行官黄耀弛先生在致答谢词时强调,该举措巩固了集团致力于提升赞比亚经济潜力、农业发展和就业水平的长期承诺。本次活动展示了多项价值数亿美元的制造业扩建及基础设施升级项目,旨在将赞比亚打造成中东非地区的核心工业强国。​在这项50亿美元的投资承诺中,园区内大规模的化工与化肥厂建设处于核心地位。继投资6.8亿美元的一期尿素生产厂竣工并投入运营后,集团正在稳步推进投资3.00亿美元的农化磷肥厂建设,预计将于第一季度投产,用于生产专用二铵(DAP)化肥。进一步的扩建计划还包括投资16亿美元的二期尿素项目和投资7.00亿美元的磷肥扩建项目,同时集团还将努力吸引更多绿色与高新技术投资者入驻运营。​为了支持这一工业增长并优化大宗运输物流,绝妙集团宣布了多项基础设施升级计划,包括升级连接当地矿山并穿过该工业园区的区域铁路网络、将蒙格维路(Mungwi Road)的部分路段改造为双向四车道,以及拓宽通往蒙布瓦路(Mumbwa Road)的连接线。这些基础设施项目将在完成内部财务手续后,通过政府与社会资本合作(PPP)模式实施,以畅通交通流量并缩短物资交付时间。黄耀弛先生对关键金融合作伙伴表达了谢意,向由艾莎银行(Absa Bank PLC)和赞比亚国家商业银行(ZANACO Bank PLC)牵头的银行银团为相关建设提供资金支持致以深切感谢。​在澄清公司身份时,黄耀弛先生指出,尽管早期外界存在误解,但绝妙集团和联合资本化肥公司均是值得骄傲的赞比亚本土企业。他强调,管理层中仅有两名中国籍员工,且均未直接参与日常运营,企业的行政控制权与管理权完全掌握在赞比亚本地人手中。黄耀弛先生重申了集团的承诺,并对赞比亚实现自产自销、对外出口以及引领东非和南部非洲工业未来的能力表达了坚定信心。